0001267565 false 0001267565 2020-02-05 2020-02-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 6, 2020

 

COLLEGIUM PHARMACEUTICAL, INC.

(Exact name of registrant as specified in its charter)

 

Virginia   001-37372   03-0416362
(state or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

    

100 Technology Center Drive

Suite 300

Stoughton, MA

  02072
(Address of principal executive offices)  (Zip Code)

 

Registrant’s telephone number, including area code: (781) 713-3699

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicated by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per share COLL The NASDAQ Global Select Market

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

On February 6, 2020, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing that it has entered into a definitive agreement to acquire the U.S. rights to the Nucynta franchise of pharmaceutical products from Assertio Therapeutics, Inc. (“Assertio”). In connection with this announcement, the Company is making available on its website a copy of a presentation which provides an overview of the transaction between the Company and Assertio. A copy of the press release and the presentation are attached hereto as Exhibits 99.1 and 99.2, respectively.

 

In accordance with general instruction B.2 to Form 8-K, the information in this Item 7.01, including the press release and presentation incorporated by reference herein, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any other filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)      Exhibits.
 
Exhibit
No.
  Description
99.1   Press Release, dated February 6, 2020.
99.2   Investor Presentation, dated February 6, 2020.
104   Cover Page Interactive Data File - the cover page XBRL tags are embedded within Inline XBRL document.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Collegium Pharmaceutical, Inc.
   
  By: /s/ Paul Brannelly
    Paul Brannelly
    Executive Vice President and Chief Financial Officer

Dated: February 6, 2020